Helping patients with insomnia: A guide for the primary care physician

Journal of Clinical Outcomes Management

Volumn 15, Issue 4, 2008, Pages 191-201

  Swanson, Leslie M ^a,b   Arnedt, J Todd ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; MIRTAZAPINE; OLANZAPINE; QUAZEPAM; QUETIAPINE; RAMELTEON; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; BEHAVIOR THERAPY; CASE REPORT; CLINICAL DECISION MAKING; CLINICAL EXAMINATION; COGNITIVE THERAPY; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DRUG CHOICE; DRUG DEPENDENCE; DRUG HALF LIFE; FATIGUE; FEMALE; HUMAN; INSOMNIA; PATIENT COUNSELING; PRACTICE GUIDELINE; PSYCHOLOGIC ASSESSMENT; REBOUND; RELAXATION TRAINING; REVIEW; SEDATION; SIDE EFFECT; SLEEP; SLEEP DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT PLANNING;

EID: 42449118834     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
2. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
3. NIH state of the science conference statement on manifestations and management of chronic insomnia in adults statement. J Clin Sleep Med 2005;1:412-21.
4. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999;22 Suppl 2:S347-53.
5. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
6. Morin CM, LeBlanc M, Daley M, et al. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006;7:123-30.
7. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-8.
8. Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007;30:873-80.
9. Taylor DJ, Lichstein KL, Durrence HH, et al. Epidemiology of insomnia, depression, and anxiety. Sleep 2005;28:1457-64.
10. Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213-8.
11. Godet-Cayre V, Pelletier-Fleury N, Le Vaillant M, et al. Insomnia and absenteeism at work. Who pays the cost? Sleep 2006;29:179-84.
12. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005;53:955-62.
13. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-23.
14. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep 2007;30:263-73.
15. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987;10:541-53.
16. Drake C, Richardson G, Roehrs T, et al. Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep 2004;27:285-91.
17. Bastien CH, Vallieres A, Morin CM. Precipitating factors of insomnia. Behav Sleep Med 2004;2:50-62.
18. Jefferson CD, Drake CL, Scofield HM, et al. Sleep hygiene practices in a population-based sample of insomniacs. Sleep 2005;28:611-5.
19. Morin C. Insomnia: psychological assessment and management. New York: Guilford; 1993.
20. Bonnet MH, Arand DL. 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep 1995;18:581-8.
21. Robertson JA, Broomfield NM, Espie CA. Prospective comparison of subjective arousal during the pre-sleep period in primary sleep-onset insomnia and normal sleepers. J Sleep Res 2007;16:230-8.
22. Morin CM, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther 2002;40:741-52.
23. Van Egeren L, Haynes SN, Franzen M, Hamilton J. Presleep cognitions and attributions in sleep-onset insomnia. J Behav Med 1983;6:217-32.
24. Morin CM, Vallieres A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007;30:1547-54.
25. Chung KF. Insomnia subtypes and their relationships to daytime sleepiness in patients with obstructive sleep apnea. Respiration 2005;72:460-5.
26. Kushida CA. Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. Am J Med 2007;120:S4-S12.
27. Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol 2004;115:1965-74.
28. American Academy of Sleep Medicine. International classification of sleep disorders: diagnostic and coding manual. Westchester (IL): The Academy; 2005.
29. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-91.
30. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
31. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128-47.
32. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
33. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-97.
34. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-7.
35. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-83.
36. Spitzer RL, Kroenke K, Williams TB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient health questionnaire. JAMA 1999;282:1737-44.
37. Buysse DJ, Reynolds CF 3rd, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD. Sleep 1994;17:630-7.
38. Benca RM. Sleep in psychiatric disorders. Neurol Clin 1996;14:739-64.
39. Fava M, McCall WV, Krystal A, et al. Eszopiclone coadministered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60.
40. Morin CM, Kowatch RA, Wade JB. Behavioral management of sleep disturbances secondary to chronic pain. J Behav Ther Exp Psychiatry 1989;20:295-302.
41. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-5.
42. Lichstein KL, Wilson NM, Johnson CT. Psychological treatment of secondary insomnia. Psychol Aging 2000;15:232-40.
43. Walsh TK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-5.
44. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7.
45. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159:5-11.
46. Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005;6:107-13.
47. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50.
48. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33.
49. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169.
50. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
51. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-68.
52. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90.
53. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504.
54. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166:1775-82.
55. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005;20:1151-8.
56. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep 1987;10:45-56.
57. Bootzin RR, Nicassio PM. Behavioral treatments for insomnia. In: Hersen M, Eisler R, Miller P, editors. Progress in behavior modification. New York: Academic Press; 1978:1-45.
58. Morin CM, Hauri PJ, Espie CA, et al. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999;22:1134-56.
59. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172-80.
60. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995;63:79-89.
61. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006;29:1398-414.
62. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006;25:3-14.
63. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851-8.
64. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004;164:1888-96.
65. Morin CM. Combined therapeutics for insomnia: should our first approach be behavioral or pharmacological? Sleep Medicine 2006;7:S15-S9.
66. McClusky HY, Milby JB, Switzer PK, et al. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. Am J Psychiatry 1991;148:121-6.
67. Wohlgemuth WK, Krystal AD. Hypnotics should be considered for the initial treatment of chronic insomnia. Pro J Clin Sleep Med 2005;1:120-4.
68. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol 2005;23:6083-96.